Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 15/20 | 0.54 |
| ▸ | CYP11B1 | P15538 | 14/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.50 |
| ▸ | NSD2 | O96028 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30751861 | 1.00 | CYP11B2 (0.54) | CYP11B2CYP11B1TAAR1TRPV4NSD2 | |
| SCHEMBL3158141 | 0.85 | TRPV4 (0.57) | CYP11B2CYP11B1TRPV4NSD2LOXL2 | |
| SCHEMBL9612021 | 0.85 | CYP11B2 (0.68) | CYP11B2CYP11B1TRPV4 | |
| Hydrochloric Acid SCHEMBL6778748 | 0.84 | TRPV4 (0.55) | CYP11B2CYP11B1TRPV4NSD2LOXL2 | |
| Hydrochloric Acid SCHEMBL21798388 | 0.84 | TRPV4 (0.55) | CYP11B2CYP11B1TRPV4NSD2LOXL2 | |
| SCHEMBL18297999 | 0.83 | CYP11B2 (0.67) | CYP11B2CYP11B1TRPV4 | |
| SCHEMBL19187744 | 0.83 | CYP11B1 (0.54) | CYP11B2CYP11B1TRPV4 | |
| SCHEMBL21266065 | 0.81 | CYP11B2 (0.51) | CYP11B2CYP11B1TAAR1 | |
| SCHEMBL30751827 | 0.81 | CYP11B2 (0.51) | CYP11B2CYP11B1TAAR1 | |
| SCHEMBL20168408 | 0.81 | CYP11B2 (0.50) | CYP11B2CYP11B1NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3535258-B1 | SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-11-24 | — | — | EP | disclosed |
| US-10723723-B2 | Substituted bicycle heterocyclic derivatives useful as ROMK channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-07-28 | — | — | US | disclosed |
| EP-3535258-A1 | SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS | Bristol-Myers Squibb Company (US) | 2019-09-11 | — | — | EP | disclosed |
| US-20190248769-A1 | SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-15 | — | — | US | disclosed |
| WO-2018093569-A1 | SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018093569-A1 | SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10723723-B2 | Substituted bicycle heterocyclic derivatives useful as ROMK channel inhibitors | KCNB1, CACNA1E, GRK1 | CYP11B2 306/4885CYP11B1 143/4885TAAR1 874/4885 |
| US-20190248769-A1 | SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS | KCNB1, CACNA1E, GRK1 | CYP11B2 306/4885CYP11B1 143/4885TAAR1 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.